Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

German pharmaceutical company Bayer (BAYRY) said on Wednesday it has entered into a global license agreement with China’s Suzhou Puhe BioPharma Co. for its oral drug candidate targeting cancer cells.

German drugmaker Bayer (BAYN: DE) has signed a global licensing agreement with China-based Puhe BioPharma, gaining exclusive ...

The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of ...

Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF ...

NPPA asks Bayer Zydus Pharma to continue selling Urografin for one more year: Gireesh Babu, New Delhi Saturday, March 29, 2025, 08:00 Hrs [IST] The National Pharmaceutical Pricing ...

Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.

in a Series A round designed to bring part of its pipeline of central nervous system and cardiometabolic drugs into the clinic. AGT-100216, Augustine's lead program, targets a group of genetic ...

FRANKFURT, March 26 (Reuters) - Bayer (BAYGn.DE), opens new tab said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China's Puhe ...